Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Receptor-mediated Endocytosis01:38

Receptor-mediated Endocytosis

Overview
Mechanisms of Drug Absorption: Paracellular, Transcellular, and Vesicular Transport01:23

Mechanisms of Drug Absorption: Paracellular, Transcellular, and Vesicular Transport

Drugs need to permeate cell membranes to reach their target sites after administration. Orally administered drugs must transcend intestinal epithelial membrane barriers to infiltrate the systemic circulation. Drugs with a molecular weight of less than 500 Daltons diffuse through gaps between neighboring cells, called paracellular pathways.
However, most drugs use the transcellular route, traversing directly through the cell membranes via two mechanisms: passive and active transport. Passive...
Ligand Binding Sites02:40

Ligand Binding Sites

Proteins are dynamic macromolecules that carry out a wide variety of essential processes; however, the activities of most proteins depend on their interactions with other molecules or ions, known as ligands.
Protein-ligand interactions are quite specific; even though numerous potential ligands surround a cellular protein at any given time, only a particular ligand can bind to that protein. Moreover, a ligand binds only to a dedicated area on the surface of the protein, known as the...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of 2H-Pyrrolo[3,4‑<i>c</i>]pyridin-3-one Derivatives as Type-III c‑MET Inhibitors Enabled by Free-Energy Perturbation Calculations.

ACS medicinal chemistry letters·2026
Same author

Development of a pKa predictor (pKaLearn) by leveraging teaching experience to improve machine learning.

Communications chemistry·2026
Same author

Integration of computational and experimental techniques for the discovery of PL<sup>pro</sup> covalent inhibitors. When large virtual screening and rational design meet.

European journal of medicinal chemistry·2026
Same author

α-Ketoamides-based covalent inhibitors in drug discovery: Current status and synthetic methods.

European journal of medicinal chemistry·2026
Same author

Inhibitor-induced dimerization mediates lufotrelvir resistance in mutants of SARS-CoV-2 3C-like protease.

Protein science : a publication of the Protein Society·2025
Same author

Mechanistic Characterization of Covalent Enzyme Inhibition by Isothermal Titration Calorimetry Kinetic Competition (ITC-KC).

Analytical chemistry·2025

Related Experiment Video

Updated: May 8, 2026

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

Methods for docking small molecules to macromolecules: a user's perspective. 1. The theory.

Nathanael Weill, Eric Therrien, Valérie Campagna-Slater

  • 1Department of Chemistry, McGill University, 801 Sherbrooke St W, Montreal, QC, Canada H3A 0B8. nicolas.moitessier@mcgill.ca.

Current Pharmaceutical Design
|August 17, 2013
PubMed
Summary
This summary is machine-generated.

This review simplifies computational protein-ligand docking for non-experts. It covers essential theory, best practices, and common pitfalls in computer-aided drug design to ensure accurate results.

More Related Videos

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

Related Experiment Videos

Last Updated: May 8, 2026

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins
05:08

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis
08:49

Incorporating Target Protein Structure Flexibility and Dynamics in Computational Drug Discovery Using Ensemble-Based Docking Analysis

Published on: June 20, 2025

Area of Science:

  • Computational chemistry
  • Molecular modeling
  • Drug discovery

Background:

  • Computational docking is a key strategy in computer-aided drug design.
  • Existing docking tools often obscure underlying theory, requiring basic knowledge for correct use.
  • Common errors and essential information for non-experts are compiled.

Purpose of the Study:

  • To provide non-experts with the necessary knowledge for effective protein-ligand docking.
  • To review docking theory, scoring functions, and recent advancements.
  • To outline optimal procedures for docking experiments and analysis.

Main Methods:

  • Review of docking theory, scoring functions, and limitations.
  • Discussion of protein flexibility, water molecules, metal ions, and covalent drugs.
  • Step-by-step guide to selecting software, databases, preparing molecules, and post-docking analysis.

Main Results:

  • Identification of common pitfalls and biases in docking experiments.
  • Compilation of essential information for accurate docking.
  • Explanation of advanced considerations like protein flexibility and covalent inhibitors.

Conclusions:

  • Understanding docking fundamentals is crucial for avoiding misinterpretations.
  • A systematic approach to docking, from preparation to analysis, ensures reliable results.
  • This review serves as a practical guide for non-experts in computational drug design.